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ABSTRACT
Infection control measures have been responsible for a decline in the prevalence of 
hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in hemodialysis patients. In 
Brazil, these measures have been in place since 1996. The aim of this study was to evaluate 
the current HBV and HCV epidemiology among hemodialysis patients in the State of 
Tocantins comparing them with those found 14 years ago. There was a significant decline 
in hepatitis B surface antigen (HBsAg) and anti-HCV prevalence from 4% and 13% in 2001 
to 0.8% and 2.8% in 2014-2015, respectively (p < 0.05). Variables related to hemodialysis 
environment such as working shift and length of time on hemodialysis treatment were no 
longer associated to HCV and HBV exposure in 2014-2015. A high prevalence of self-reported 
hepatitis B vaccination was observed in both periods, but only 30% of the individuals showed 
serological profile of effective previous immunization, suggesting a low compliance with 
surveillance of hepatitis B immunization in hemodialysis centers. The significant decline 
in viral hepatitis B and C prevalence in hemodialysis patients in Tocantins underscores the 
importance of infection control measures, but the low frequency of protective serological 
profile after immunization against hepatitis B points to the need for greater vigilance of the 
patients’ vaccination. 
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INTRODUCTION
Globally, about 257 million and 71 million people are chronically infected with 
hepatitis B virus (HBV) and hepatitis C virus (HCV), respectively, and are at risk 
of developing cirrhosis and liver cancer. These infections have been the cause of 
1.34 million deaths in 20151. 
Chronic Kidney Disease (CKD) is a public health problem worldwide. In Brazil, 
the incidence and prevalence of renal failure are increasing, the prognosis is still 
poor and treatment costs are high2. 
HBV and HCV are efficiently transmitted parenterally and these viruses have 
been a historical cause of comorbidities among hemodialysis patients. High 
prevalences of viral hepatitis B and C have been observed in hemodialysis centers 
worldwide. In general, these individuals are exposed to several risk factors for viral 
hepatitis B and C, including blood transfusion, invasive medical procedures and 
sharing of infected patients’ environments3,4. 
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Unlike HCV, HBV infection can be prevented by 
vaccination. The HBV vaccine has been available and 
recommended for all hemodialysis patients since the 1980s5. 
However, this virus remains a major public health problem, 
especially in developing countries with limited resources 
for hemodialysis patients, attended by health professionals 
who are less compliant with infection prevention and control 
measures6,7. 
Studies show that the adoption of specific measures for 
infection control and prevention in hemodialysis centers 
contributes in a decisive way toward reducing the rates of 
HBV and HCV infections during hemodialysis8-10. In the 
USA, in the early 1970s, the incidence of HBV infection 
among chronic hemodialysis patients was 6.2%, declining 
to 1% by 1980 following the adoption of control and 
prevention measures, and to 0.06% by 1999 following the 
inclusion of the hepatitis B vaccine8. 
In Brazil, over the last 20 years, through public policies, 
infection control and prevention measures have been 
incorporated into the routine of hemodialysis centers. 
Monitoring of patients for viral hepatitis has become 
compulsory; the hepatitis B vaccine has become mandatory 
for all hemodialysis patients and health professionals; 
hepatitis B surface antigen (HBsAg) reagent patients are 
dialyzed in a segregated room and machine and by exclusive 
personnel11,12. However, information on the impact of these 
measures on the endemicity of hepatitis B and C in dialysis 
centers in the country is scarce13. 
In 2001, this research group had the opportunity to 
investigate the epidemiology of hepatitis B and C in 
hemodialysis patients in the State of Tocantins, in the 
Northern region of the country. In the study period, there 
was only one hemodialysis center in the state, which 
served 100 patients. In that study, a prevalence of 16% for 
anti-HCV was observed. For hepatitis B, 45% had been 
exposed to HBV (anti-HBc positive) and 4% were chronic 
carriers (HBsAg positive). Moreover, the study findings 
suggested that the hemodialysis environment played a role 
in viral dissemination14. The purpose of this study was to 
evaluate the impact of public policies for infection control 
and prevention in the epidemiology of viral hepatitis B and 
C in individuals undergoing hemodialysis in the State of 
Tocantins, located in the Northern region of Brazil.
MATERIAL AND METHODS
According to a population-based multicenter survey, 
the Northern region of Brazil has low HBV and HCV 
endemicity15. Tocantins is a State located in this region 
and occupies an area of 277,720,569 km2 being the newest 
State in Brazil (IBGE, 2017). It has a human development 
index (HDI) of 0.699 and a population of 1,497 million 
inhabitants. The main economic activities of the State are 
agriculture, cattle raising, extractivism and services. 
In 2001, there was only one hemodialysis center located 
in the city of Gurupi, as previously described by Souza et 
al.14. In 2014-2015, there were four centers of hemodialysis, 
which served 434 individuals in the three largest cities in the 
State: Palmas (2 centers, 265,409 inhabitants), Araguaina 
(1 center, 167,176 inhabitants) and Gurupi (1 center; 82,762 
inhabitants). In these centers, all patients susceptible to 
viral hepatitis B and C were regularly monitored for HBV 
and HCV markers; HBsAg positive and anti-HCV positive 
patients were dialyzed in separate rooms and by exclusive 
nursing staff. Hemodialyzers used by patients positive for 
these markers were discarded after use and patients were 
vaccinated against hepatitis B.
This study was conducted in all working hemodialysis 
centers in the State of Tocantins. During the study period 
(October 2014 to February 2015), there were 434 chronic 
care patients being treated in the morning, afternoon 
and evening shifts. All patients aged 18 years or older 
on hemodialysis treatment for at least six months were 
included. Patients on acute hemodialysis were excluded.
A total of 425 individuals were eligible and 394 (92.7%) 
participated in the study. All participants were interviewed 
on sociodemographic data, risk factors for viral hepatitis, 
and prior vaccination against hepatitis B.
After the interview and immediately before starting the 
hemodialysis treatment, 10 mL of blood were collected 
for the detection of HBV markers: HBsAg, anti-HBs and 
total anti-HBc by enzyme-linked immunosorbent assay 
using commercial kits (Hepanostika Ultra, Biomerieux and 
Biokit), as well as anti-HCV (Abbott Laboratories, Brazil).
Descriptive analysis was performed by frequencies, 
mean and standard deviation. Prevalences and Odds Ratios 
were calculated with 95% confidence intervals (95% CI). 
The Chi-squared test (χ2) or Fisher’s exact tests were used 
to compare categoric variables, and Student’s t-test for 
continuous variables. Values of p < 0.05 were considered 
statistically significant. Data were compared to the ones 
collected by the research team 14 years ago12. 
This study was approved by the Ethics Committees of 
the Fundação Pró-Rim, (Protocol Nº 054/2014) and Centro 
Universitário UnirG (protocol Nº 845.445). 
RESULTS
The age of the patients was recorded. In 2001, the 
average age was 47.6 years (range: 13-82 years), while 
in 2015 it was 53.4 years (range: 18-90). There was a 
predominance of men in both study periods (62% vs. 
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58.6%). The proportion of hemotransfused individuals 
decreased significantly from 2001 to 2014-2015 (96% vs. 
76.3%). In 2001, only 27% were in treatment for more than 
36 months and this percentage reached 54.1% in 2014-2015. 
Since that time, a new shift was added for treatment and 
28.2% of the hemodialysis patients underwent night shifts 
treatment in 2014-2015. Regarding vaccination against 
hepatitis B, in both periods, there was a large vaccination 
coverage, almost all patients received three or more doses 
of the vaccine (94% vs. 97.2%) (Table 1).
As shown in Figure 1, in 2001, the prevalence of 
HBsAg and anti-HBc was 4% and 45%, respectively, 
declining to 0.8% and 35.6% in 2014-2015 (p < 0.05). 
On the other hand, similar prevalence rates were found 
for anti-HBs isolated (27.9% vs. 29.4%). Concerning 
anti-HCV, the prevalence was 13%, dropping to 2.8% in 
2014-2015 (p < 0.05).
As shown in Table 2, in 2001, individuals who 
underwent hemodialysis treatment during second shift 
had almost three-fold more chance to be exposed to the 
hepatitis B virus (OR 2.78; CI 95%: 1.14-6.88) compared 
to those dialyzed in the first shift. Further length of time 
on hemodialysis (greater than three years) was a predictor 
of HCV infection (OR 19.2; CI 95%: 2.17-69.4). In 2014-
2015, these variables were not associated with viral hepatitis 
markers. 
DISCUSSION
Over the last three decades, the implementation of 
infection control and prevention measures in hemodialysis 
centers has been credited with an abrupt reduction in the 
endemicity of viral hepatitis B and C8. In Brazil, these 
measures were effectively implemented since 1996 through 
regulations from the Ministry of Health11,12, and certainly 
played a decisive role in reducing the prevalence of HBV 
and HCV infection in hemodialyzed patients in Tocantins14. 
In 2001, there was only one hemodialysis center in this 
State, which served 100 patients. Fourteen years later this 
number quadrupled and despite the increase in demand 
there was a decline in the endemicity of viral hepatitis B 
(HBsAg: 4% vs 0.8%; p<0.05) and C (anti-HCV: 13% vs. 
2.8%; p < 0.0001). 
Hemodialysis patients are routinely subjected to 
invasive procedures including punctures and extracorporeal 
circulation. In addition, they share the hemodialysis 
environment with many individuals with infectious diseases 
such as hepatitis B and C. Furthermore, they generally 
show impaired humoral and cellular immune response 
and consequently lower response to hepatitis B vaccine6. 
This conjunction of factors has been responsible for the 
strict association between viral exposure and hemodialysis 
treatment. In fact, in the prior study the dialysis environment 






frequency % frequency %
Age (mean; range) 47.6 (13-82) 53.4 (18-90) > 0.05a
Male sex 62 62.0 231 58.6 > 0.05b
Previous blood transfusion*
No 04 4.0 92 23.7
Yes 95 96.0 297 76.3 < 0.001c
Length of hemodialysis (months)
< 12 29 29.0 40 10.2
12-36 44 44.0 141 35.8 < 0.001b
>36 27 27.0 213 54.1
Shift
Morning 47 47.0 138 35.0
Afternoon 53 53.0 145 36.8 < 0.001b
Evening 0 - 111 28.2
Report of previous hepatitis B vaccine
< 3 doses 06 6.0 11 2.8
≥ 3 doses 94 94.0 383 97.2 > 0.05b
*Missing value 2001: 01; missing values 2014-2015: 05. aStudent´s t-test; bχ2 test; cFisher´s exact test
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probably played a role in viral dissemination14. In 2001, 
individuals who underwent evening shift treatment were 
2.78 times more likely to be exposed to HBV, suggesting 
some failure to control infection between shifts. In relation 
to hepatitis C, the chance of exposure was almost 20 times 
greater [Odds Ratio (OR): 19.25] after three years on 
hemodialysis.
On the other hand, this study was not able to identify 
these environmental variables as predictors of viral B 
and C exposure in 2014-2015. Most likely compliance 
with infection control measures contributed to reducing 
the chances of transmission in the dialysis environment. 
In addition, it should be pointed out that there is still 
controversy regarding the effectiveness of segregation of 
patients by room, machineand nursing personnel in the 
hemodialysis treatment of anti-HCV positive patients16. In 
Tocantins this strategy is used in all hemodialysis centers. 
Therefore, additional studies will be needed to analyze the 
role of this specific measure for the prevention of hepatitis 
C in the dialysis environment in Tocantins.
Table 2 - Comparison of epidemiological data on hepatitis B and C between the years 2001 and 2014-2015 among hemodialysis 
patients in Tocantins, Northeastern Brazil
Risk factor
2001 2015
n HBV+ (%) OR (95% CI) HCV+ (%) OR (95% CI) n HBV+ (%) OR (95% CI) HCV+ (%) OR (95% CI)
Length of time on 
hemodialysis
< 1year 29 14 (44.3) 1.0 1 (3.4) 1.0 40 10 25.0 1 2.6 1.00
1 – 3 years 44 17 (38.6) 0.67 
(0.23 – 1.93)
4 (9.1) 2.8 
(0.27 – 69.4)
141 52 36.9 1.75 
(0.79-3.87)
1 0.7 0.28 
(0.02-4.52)
> 3 years 27 14 (51.8) 1.15 
(0.35 – 3.76)
11 (40.7) 19.2 
(2.17- 436.5)
213 73 34.3 1.56 
(0.72-3.38)
9 4.2 1.68 
(0.20-13.62)
Shift*
First 47 15 (31.9) 1.0 9 (19.1) 1.0 138 48 34.8 2 1.4 1.00
Second 53 30 (56.6) 2.78 
(1.14 – 6.88)
7 (13.2) 0.64 
(0.19 – 2.12)
145 49 33.8 0.96 
(0.59-1.56)
4 2.8 1.93 
(0.358-10.7)
Third - - - 111 38 34.2 0.98 
(0.58-1.65)
5 4.5 3.24 
(0.61-17.02)
n: number of patients; OR: odds ratio; CI: confidence interval; * Considered for calculation, only patients dialyzed during first or second shift
Figure 1 - Prevalence of HBV and HCV serological markers among hemodialysis patients in Tocantins, Northern Brazil, 2001 and 
2014-2015; * p < 0.05
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In the past, blood transfusion was responsible for most 
cases of viral hepatitis B and C in hemodialysis centers. 
However, in countries that included the serological 
screening of these infections in their blood banks, cases 
of post-transfusional viral hepatitis have become rare. In 
Brazil, serological screening for HBsAg in blood banks 
started in 1989, and for anti-HBc and anti-HCV in 199317. 
Therefore, although the majority (75%) of hemodialysis 
patients investigated had reported previous blood 
transfusions, almost all of them were transfused after 1993 
(data not shown). This measure may also have contributed to 
the decline in the endemicity of these infections in Tocantins 
dialysis centers.
Interestingly, although the vaccine coverage of 
hepatitis B in hemodialysis is high, the serological profile 
of previous immunization does not confirm the effective 
immunization status of these individuals. In both periods, 
only approximately 30% of hemodialysis patients had 
isolated positivity for anti-HBs. Unfortunately, we do not 
have information on the vaccine response shortly after 
the primary vaccination scheme, and on booster doses 
for non-responders, or for those who have not maintained 
post-vaccine anti-HBs protective titers. However, the low 
frequency of individuals with serological profile of HBV 
immunization is worrisome and suggests failure to monitor 
anti-HBs.
In fact, this discrepancy between vaccination reports and 
low frequency of isolated positivity for anti-HBs probably 
reflects the gradual decline in anti-HBs over the years. In 
healthy individuals, more than 90% respond to vaccination 
and show anti-HBs protective titers, remaining immune 
to HBV for at least 30 years, even with titers declining to 
undetectable levels, since immunological memory induces 
the formation of protective antibodies when there is an 
antigenic challenge18. On the other hand, in individuals with 
chronic kidney disease, these dynamic changes. In general, 
due to aging and immunosuppression, there is less vaccine 
response, and more frequent doses are required. In addition, 
anti-HBs titers decrease to non-protective levels more rapidly. 
For these individuals, unlike the healthy population, anti-HBs 
monitoring should be done regularly and booster doses should 
be performed when anti-HBs titers are less than 10 mUI/mL, 
because of the risk of infection. In fact, outbreaks of viral 
hepatitis in the dialysis environment are not uncommon when 
infection control breaches occur3,4,7. Kliner et al.19 reported 
patient-to-patient transmission of HBV in a UK hemodialysis 
unit. According to these authors, the occurrence of this kind 
of event was attributed to non-compliance with infection 
control and prevention recommendations, which includes 
monitoring anti-HBs titers to indicate vaccination booster 
doses, when appropriate.
Some limitations of the study should be considered. 
The number of participants was insufficient to analyze 
potential risk factors for hepatitis C, however, representing 
92.7% of the individuals undergoing chronic hemodialysis 
in the State of Tocantins. The vaccine card of the 
individuals undergoing hemodialysis was not verified, 
therefore, the information on the vaccination situation 
was collected through patient self-reports, which could 
be mistaken for memory bias.
This study provides valuable information on the 
epidemiology of viral hepatitis B and C at hemodialysis 
centers in Tocantins, Northern region of Brazil. Although 
the reductions in HBsAg and anti-HCV prevalence 
observed between 2001 and 2014-2015resulted from 
the efforts of managers and hemodialysis professionals 
to comply with infection control measures, the low 
proportion of individuals with a serological profile of prior 
immunization to hepatitis B suggests some weaknesses in 
monitoring the persistence of protective anti-HBs titers, 
a key strategy for the prevention of hepatitis B in the 
dialysis environment.
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